Biosensing of arteriosclerotic nanoplaque formation and interaction with an HMG-CoA reductase inhibitor

Acta Physiologica Scandinavica

Volumn 176, Issue 2, 2002, Pages 131-145

  Abletshauser, C ^a   Klußendorf D ^a   Schmidt, A ^a   Winkler, K ^a   Marz W ^a   Buddecke, E ^a   Malmsten, M ^a   Siegel, G ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Arteriosclerosis model; Calcification; Ellipsometry; Fluvastatin therapy; Lipoproteins; Proteoglycan receptor

Indexed keywords

CALCIUM ION; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PROTEOGLYCAN; VERY LOW DENSITY LIPOPROTEIN;

ADSORPTION; ARTICLE; ATHEROSCLEROTIC PLAQUE; BINDING AFFINITY; CALCIUM BLOOD LEVEL; CASE REPORT; COMPLEX FORMATION; DRUG EFFECT; DYSLIPOPROTEINEMIA; ELLIPSOMETRY; GENETIC PROCEDURES; HIGH RISK PATIENT; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PLEIOTROPY; PRIORITY JOURNAL; RISK FACTOR;

ADSORPTION; ARTERIOSCLEROSIS; BINDING SITES; CALCIFICATION, PHYSIOLOGIC; CALCIUM; FATTY ACIDS, MONOUNSATURATED; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; SILICON DIOXIDE; TIME FACTORS;

EID: 0036407158     PISSN: 00016772     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-201X.2002.01020.x     Document Type: Article

References (62)

1. Al-Haideri, M., Goldberg, I.J., Galeano, N.F. et al. 1997. Heparan sulfate proteoglycan-mediated uptake of apolipoprotein E-triglyceride-rich lipoprotein particles: A major pathway at physiological particle concentrations. Biochemistry 36, 12766-12772.
2. Anber, V., Millar, J.S., McConnell, M., Shepherd, J. & Packard, C.J. 1997. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler Thromb Vasc Biol 17, 2507-2514.
3. Atkins, E.D.T. 1977. Molecular architecture of the animal and some microbial extracellular polysaccharides. In: A.G. Walton (ed.) Proceedings of the First Cleveland Symposium on Macromolecules. Structure and Properties of Biopolymers, pp. 61-85. Elsevier, Amsterdam.
4. Azzam, R.M.A. & Bashara, N.M. 1989. Ellipsometry and Polarized Light. North-Holland, Amsterdam.
5. Ballantyne, C.M., McKenney, J. & Trippe, B.S. 2000. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. Am J Cardiol 86, 759-763.
6. Brown, B.G., Zhao, X.-Q., Sacco, D.E. & Albers, J.J. 1993. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 87, 1781-1791.
7. Camejo, G., Hurt-Camejo, E., Wiklund, O. & Bondjers, G. 1998. Association of apo B lipoproteins with arterial proteoglycans: Pathological significance and molecular basis. Atherosclerosis 139, 205-222.
8. Chait, A., Chang, M.Y., Olin, K. & Wight, T. 1997. Interaction of oxidized LDL with arterial proteoglycans. Atherosclerosis 134, 197.
9. Cohen Stuart, M.A. 1998. Macromolecular adsorption: a brief introduction. In: M. Malmsten (ed.) Biopolymers at Interfaces, pp. 1-25. Marcel Dekker, New York.
10. Corti, R., Fayad, Z.A., Fuster, V. et al. 2001. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions. A longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 104, 249-252.
11. Davies, M.J. 1996. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 94, 2013-2020.
12. De Feijter, J.A., Benjamins, J. & Veer, F.A. 1978. Ellipsometry as a tool to study the adsorption behavior of synthetic and biopolymers at the air-water interface. Biopolymers 17, 1759-1772.
13. Derendorf, H., Möllmann, H., Hochhaus, G., Meibohm, B. & Barth, J. 1997. Clinical PK/PD modelling as a tool in drug development of corticosteroids. Int J Clin Pharmacol Therap 35, 481-488.
14. Deslypere, J.P. 1995. The role of HMG-CoA reductase inhibitors in the treatment of hyperlipidemia: a review of fluvastatin. Curr Therap Res 56, 111-128.
15. Edwards, I.J., Goldberg, I.J., Parks, J.S., Xu, H. & Wagner, W.D. 1993. Lipoprotein lipase enhances the interaction of low density lipoproteins with artery-derived extracellular matrix proteoglycans. J Lipid Res 34, 1155-1163.
16. Falk, E., Shah, P.K. & Fuster, V. 1995. Coronary plaque disruption. Circulation 92, 657-671.
17. Fransson, L.-Å. 1987. Structure and function of cell-associated proteoglycans. Trends Biochem Sci 12, 406-411.
18. Galis, Z.S., Muszynski, M., Sukhova, G.K., Simon-Morrissey, E. & Libby, P. 1995. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann NY Acad Sci 748, 501-507.
19. Georgiou, D., Budoff, M.J., Kaufer, E., Kennedy, J.M., Lu, B. & Brundage, B.H. 2001. Screening patients with chest pain in the emergency department using electron beam tomography: a follow-up study. J Am Coll Cardiol 38, 105-110.
20. Gordon, D.J. & Rifkind, B.M. 1989. High-density lipoprotein: The clinical implications of recent studies. N Engl J Med 321, 1311-1316.
21. Hardingham, T.E. & Fosang, A.J. 1992. Proteoglycans: many forms and many functions. FASEB J 6, 861-870.
22. Havel, R.J., Eder, H.A. & Bragdon, J.H. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human plasma. J Clin Invest 34, 1345-1353.
23. Hiemenz, P.C. 1986. Principles of Colloid and Surface Chemistry. Marcel Dekker, New York.
24. Hussein, O., Schlezinger, S., Rosenblat, M., Keidar, S. & Aviram, M. 1997. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 128, 11-18.
25. Ji, Z.S., Dichek, H.L., Miranda, R.D. & Mahley, R.W. 1997. Heparan sulfate proteoglycans participate in hepatic lipase and apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J Biol Chem 272, 31285-31292.
26. Krieger, M. & Herz, J. 1994. Structures and functions of multiligand lipoprotein receptors: Macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 63, 601-637.
27. 2 surfaces by means of) ellipsometry, using different ambient media. J Phys Chem 97, 1656-1660.
28. Leonhardt, W., Pietzsch, J., Julius, U. & Hanefeld, M. 1994a. Recovery of cholesterol and triacylglycerol in very-fast ultracentrifugation of human lipoproteins in a large range of concentrations. Eur J Clin Chem Clin Biochem 32, 929-933.
29. Leonhardt, W., Pietzsch, J. & Nitzsche, S. 1994b. Very-fast ultracentrifugation of human plasma lipoproteins: influence of the centrifugal field on lipoprotein composition. Clin Chim Acta 224, 21-32.
30. Libby, P. 1995. Molecular bases of the acute coronary syndromes. Circulation 91, 2844-2850.
31. Lookene, A., Savonen, R. & Olivecrona, G. 1997. Interaction of lipoproteins with heparan sulfate proteoglycans and with lipoprotein lipase. Studies by surface plasmon resonance technique. Biochemistry 36, 5267-5275.
32. Malmsten, M. 1994. Ellipsometry studies of protein layers adsorbed at hydrophobic surfaces. J Colloid Interface Sci 166, 333-342.
33. Malmsten, M. & Lassen, B. 1995. Competitive adsorption at phospholipid surfaces. Colloids Surf B: Biointerfaces 4, 173-184.
34. Malmsten, M. & Siegel, G. 1995. Electrostatic and ion-binding effects on the adsorption of proteoglycans. J Colloid Interface Sci 170, 120-127.
35. Malmsten, M., Siegel, G., Buddecke, E. & Schmidt, A. 1993. Cation-promoted adsorption of proteoheparan sulphate. Coll Surf B: Biointerfaces 1, 43-50.
36. Malmsten, M., Claesson, P. & Siegel, G. 1994. Forces between proteoheparan sulfate layers adsorbed at hydrophobic surfaces. Langmuir 10, 1274-1280.
37. Malmsten, M., Lindström, A.L. & Wärnheim, T. 1996. Electrostatic effects on interfacial film formation in emulsion systems. J Colloid Interface Sci 179, 537-543.
38. Malmsten, M., Muller, D. & Lassen, B. 1997. Sequential adsorption of human serum albumin (HSA), immunoglobulin G (IgG), and fibrinogen (Fgn) at HMDSO plasma polymer surfaces. J Colloid Interface Sci 193, 88-95.
39. Malmsten, M., Siegel, G. & Wood, W.G. 2000. Ellipsometry studies of lipoprotein adsorption. J Colloid Interface Sci 224, 338-346.
40. Malmsten, M., Siegel, G. & Becker, A. 2001. A model substrate for ellipsometry studies of lipoprotein deposition at the endothelium. J Colloid Interface Sci 240, 372-374.
41. Marquardt, D.W. 1963. An algorithm for least-squares estimation of nonlinear parameters. J Soc Indust Appl Math 11, 431-441.
42. Olgemöller, B., Schleicher, E.D., Schwaabe, S., Guretzki, H.-J. & Gerbitz, K.D. 1990. High concentrations of low density lipoprotein decrease basement membrane-associated heparan sulfate proteoglycan in cultured endothelial cells. FEBS Lett 264, 37-39.
43. Ross, R. 1999. Atherosclerosis - an inflammatory disease. New Engl J Med 340, 115-126.
44. Sawamura, T., Kume, N., Aoyama, T. et al. 1997. An endothelial receptor for oxidized low-density lipoprotein. Nature 386, 73-77.
45. Schatz, I.J., Masaki, K., Yano, K., Chen, R., Rodriguez, B.L. & Curb, J.D. 2001. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 358, 351-355.
46. Schmidt, A. & Buddecke, E. 1988. Cell-associated proteoheparan sulfate from bovine arterial smooth muscle cells. Exp Cell Res 178, 242-253.
47. Shepherd, J. 1995. Fibrates and statins in the treatment of hyperlipidemia: an appraisal of their efficacy and safety. Eur Heart J 16, 5-13.
48. Siegel, G. 1996. Connective tissue: more than just a matrix for cells. In: R. Greger & U. Windhorst (eds) Comprehensive Human Physiology, Vol. 1, pp. 173-224. Springer-Verlag, Berlin, Heidelberg.
49. Siegel, G. & Malmsten, M. 1998. Plasma lipoproteins, vascular cell-cell and cell-matrix contacts and disease. Pharmacol Toxicol 83 (Suppl. I), 113-115.
50. Siegel, G., Walter, A., Rückborn, K. et al. 1991. NMR studies of cation induced conformational changes in anionic biopolymers at the endothelium-blood interface. Polymer J 23, 697-708.
51. Siegel, G., Malmsten, M., Klüßendorf, D., Walter, A., Schnalke, F. & Kauschmann, A. 1996a. Blood-flow sensing by anionic biopolymers. J Auton Nerv Syst 57, 207-213.
52. Siegel, G., Walter, A., Kauschmann, A., Malmsten, M. & Buddecke, E. 1996b. Anionic biopolymers as blood flow sensors. Biosensors Bioelectronics 11, 281-294.
53. Siegel, G., Malmsten, M., Klüßendorf, D., Walter, A. & Schmidt, A. 1997. Chemistry, recognition and function of a natural shear stress biosensor. ACS Polym Mat Sci Eng 76, 573-575.
54. Siegel, G., Malmsten, M., Klüßendorf, D., Leonhardt, W., Schmidt, A. & Buddecke, E. 1998. Physicochemical interaction between plasma lipoproteins and the endothelial cell membrane and vascular matrix proteoglycans. Atherosclerosis XI, 327-331.
55. Siegel, G., Malmsten, M. & Lindman, B. 1998. Flow sensing at the endothelium-blood interface. Coll Surf A: Physicochem Eng Aspects 138, 345-351.
56. Siegel, G., Malmsten, M., Klüßendorf, D. & Leonhardt, W. 1999. Physicochemical binding properties of the proteoglycan receptor for serum lipoproteins. Atherosclerosis 144, 59-67.
57. Siegel, G., Malmsten, M. & Michel, F. 2000. A primary lesion model for arteriosclerotic microplaque formation. Int J Angiol 9, 129-134.
58. Siegel, G., Malmsten, M., Klüßendorf, D. & Michel, F. 2001. A receptor-based biosensor for lipoprotein docking at the endothelial surface and vascular matrix. Biosensors Bioelectronics 16, 895-904.
59. Timpl, R. 1993. Proteoglycans of basement membranes. Experientia 49, 417-428.
60. Trescony, P.V., Oegema, T.R. Jr, Farnam, B.J. & Deloria, L.B. 1989. Analysis of heparan sulfate from the Engelbreth-Holm-Swarm (EHS) tumor. Connect Tissue Res 19, 219-242.
61. Vijayagopal, P., Srinivasan, S.R., Radhakrishnamurthy, B. & Berenson, G.S. 1983. Hemostatic properties and serum lipoprotein binding of a heparan sulfate proteoglycan from bovine aorta. Biochim Biophys Acta 758, 70-83.
62. Voyiaziakis, E., Goldberg, I.J., Plump, A.S., Rubin, E.M., Breslow, J.L. & Huang, L.S. 1998. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. J Lipid Res 39, 313-321.